Résumé
A case of congenital bronchial cyst in a young female is reported. Relevant literature has been reviewed.
Sujets)
Adulte , Kyste bronchogénique/congénital , Femelle , HumainsRésumé
FNAC was performed in 186 cases. Inadequate material was obtained in 41 cases. A definite diagnosis of malignancy could be made in 120 cases. In five cases a diagnosis "suspicious" of malignancy could be made. No serious complication was encountered with the technique. FNAC is of definite help in diagnosing the intra thoracic lesion whether malignant or inflammatory in nature. It also avoids unnecessary thoracotomy for diagnostic purposes.
Sujets)
Ponction-biopsie à l'aiguille , Humains , Maladies du thorax/diagnostic , Tumeurs du thorax/diagnosticRésumé
A 45-year-old female, post menopausal, presented with extensive bilateral radiological opacities in the lungs. Diagnosis of hydatid diseases was confirmed through open lung biopsy. Treatment with albendazole showed striking improvement in clinical symptoms as well as clearing of radiological shadows.
Sujets)
Albendazole/usage thérapeutique , Diagnostic différentiel , Échinococcose pulmonaire/diagnostic , Femelle , Humains , Adulte d'âge moyen , Pneumopathie infectieuse/diagnosticRésumé
A case of small cell anaplastic carcinoma of bronchus is described. Primary tumour had metastasized in the stomach and there was production of amylase by the tumour evidenced by raised serum amylase and pleural fluid amylase.
Sujets)
Sujet âgé , Amylases/biosynthèse , Carcinome bronchogénique/enzymologie , Humains , Tumeurs du poumon/anatomopathologie , Mâle , Tumeurs de l'estomac/enzymologieRésumé
Combination chemotherapy with 3 drugs (vincristine + cyclo-phosphamide + methotrexate of adriamycin) were administered to 36 cases of advanced bronchogenic carcinoma. The median survival for patients with small cell carcinoma (SCC) was 24.5 weeks whereas that for non small cell carcinoma was 27.5 weeks (P greater than 0.05). Fifty-five per cent of the patients survived beyond 6 months; 30.5 per cent survived beyond 1 year and 11 per cent of the patients survived beyond two years. Adriamycin did not prove more effective than methotrexate. However, omission of adriamycin from the regimen may reduce the cost of chemotherapy.